Is there a role for immunotherapy in malignant pleural mesothelioma?

Alfredo Tartarone, Rosa Lerose, Michele Aieta

Research output: Contribution to journalReview articlepeer-review


Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

Original languageEnglish
Article number98
JournalMedical Oncology
Issue number7
Publication statusPublished - Jul 1 2018


  • CAR T cell therapy
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Malignant pleural mesothelioma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Is there a role for immunotherapy in malignant pleural mesothelioma?'. Together they form a unique fingerprint.

Cite this